MAY 1·Stock TitanLow
CNS Pharmaceuticals (NASDAQ: CNSP) details CEO transition, pay and ownership in 10-K/A
CNS Pharmaceuticals (CNSP) filed an amended annual report (10-K/A) to update information
StockHealthcare · Biotechnology
$CNSP
CNS Pharmaceuticals, Inc.
Price · $CNSPvia TradingView
AI sentiment · 7d0 articles
No enriched coverage for $CNSP in the last 7 days.
Insider · 30dFeed →
No SEC Form 4 filings for $CNSP in the last 30 days.
Top stories · $CNSPMore →
APR 1·Stock Titan
CNS Pharmaceuticals (NASDAQ: CNSP) pivots to neurology and oncology amid going concern risk
CNS Pharmaceuticals (NASDAQ: CNSP) is undergoing a strategic pivot, shifting its focus from solely glioblastoma to building an in-licensed pipeline in neurology and oncology. This change follows the Phase 2 trial failure of its legacy asset Berubicin to demonstrate superiority over lomustine in overall survival. The company faces a going concern risk, with cash flow projections indicating it can fund operations only into the third quarter of 2026, necessitating additional capital.
APR 1·TradingView
CNS Pharmaceuticals 10-K: Net loss $15.85M, Loss per share $35.75
CNS Pharmaceuticals reported a net loss of $15.85 million for the year, primarily due to increased research and development spending for clinical programs. The company's operating loss totaled $15.99 million, with a loss per basic share of $35.75 based on 443,369 weighted average shares outstanding. They also raised equity in 2025 to fund operations and trials through mid-2026.